IONS vs CRNX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRNX Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus CRNX at N/M Forward P/E and -527.4% operating margin (+2336.3% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | CRNX Revenue | IONS Op. Margin | CRNX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | $0M | -10.2% | -1182.5% | IONS |
| FY2019 | $1.12B | $0M | 32.6% | -4512.3% | IONS |
| FY2020 | $730M | $0M | -23.6% | -105567.6% | IONS |
| FY2021 | $810M | N/A | -3.7% | N/A | IONS |
| FY2022 | $590M | N/A | -69.8% | N/A | IONS |
| FY2023 | $790M | $0M | -44.9% | -5547.2% | IONS |
| FY2024 | $710M | $0M | -67.4% | -32613.5% | IONS |
| FY2025 | $940M | $10M | -40.4% | -6714.8% | IONS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | CRNX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $9.0B | Larger Scale | CRNX |
| Trailing P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Revenue Growth (YoY) Growth | +54.9% | +2336.3% | Higher Growth | CRNX |
| Operating Margin (TTM) Profitability | -58.8% | -527.4% | Higher Margin | IONS |
| Net Profit Margin Profitability | -56.9% | 0.0% | Higher Margin | CRNX |
| Return on Equity (ROE) Capital Efficiency | -108.0% | -42.4% | Higher ROE | CRNX |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 100% ($30โ$85) | Stronger Trend | CRNX |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 0.29ฮฒ ยท 2% Vol | Lower Realized Risk | CRNX |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 46.8 / 100 (HOLD) | Higher Composite | IONS |